Epigenetic regulation in Alzheimer’s disease: is it a potential therapeutic target?
Author:
- 3 April 2021
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 25 (4) , 283-298
Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the primary form of dementia in the elderly. Changes in DNA methylation and post-translational modifications of histone tails are increasingly observed in AD tissues, and likely contribute to disease onset and progression. The reversibility of these epigenetic marks offers the potential for therapeutic interventions. After a concise and updated overview of DNA methylation and post-translational modifications of histone tails in AD tissues, this review provides an overview of the animal and cell culture studies investigating the potential of targeting these modifications to attenuate AD-like features. PubMed was searched for relevant literature between 2003 and 2021. Methyl donor compounds and drugs acting on histone tail modifications demonstrated attenuated AD-like features and improved cognition in several transgenic AD mice; however, there are concerns about safety and tolerability for long-term treatment in humans. The challenges will be to take advantage of recent epigenome-wide investigations to identify the principal targets for future interventions, and to design novel, selective and safer agents. Natural compounds exerting epigenetic properties could represent a promising opportunity to delay disease onset in middle-aged individuals at increased AD risk.Keywords
This publication has 100 references indexed in Scilit:
- Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patientsTranslational Psychiatry, 2012
- Functions of DNA methylation: islands, start sites, gene bodies and beyondNature Reviews Genetics, 2012
- An epigenetic blockade of cognitive functions in the neurodegenerating brainNature, 2012
- DNA Methylation and Demethylation in MammalsJournal of Biological Chemistry, 2011
- Regulation of chromatin by histone modificationsCell Research, 2011
- MicroRNA-101 downregulates Alzheimer’s amyloid-β precursor protein levels in human cell cultures and is differentially expressedBiochemical and Biophysical Research Communications, 2011
- Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's DiseaseNeuropsychopharmacology, 2009
- Dietary deficiency increases presenilin expression, gamma‐secretase activity, and Abeta levels: potentiation by ApoE genotype and alleviation by S‐adenosyl methionineJournal of Neurochemistry, 2009
- Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse modelsJournal of Experimental Medicine, 2008
- Histone deacetylase 6 interacts with the microtubule‐associated protein tauJournal of Neurochemistry, 2008